This ADC binds a surface antigen (e.g., TROP2) on tumor cells, is internalized, and releases a camptothecin-derived payload that inhibits topoisomerase I, causing DNA damage and cell death. TOP1 is the intracellular payload target, not the antigen the drug recognizes.